Vasculitis

Spanish Nationwide registry study of 5120 hospitalised #GCA pts (2016-2024) found that 54 (1.1%) Dx / aortic aneurysm (AA) & 41 (0.8%) developed AA on F/U (AAf group). Median time to AA Dx 2.7 yrs. AA Risk was higher in males (RRR 2.42) & smoking w/ GCA (RRR 3.23) https://t.co/eZVGKbOfQt

Monitoring ILD in SjD: reassess risk at every visit. High risk with disease duration under 1 year: PFTs every 3-6 months, HRCT at 1 year. Lung biopsy has no role in diagnosis, except for atypical HRCT features or to exclude malignancy. #APLAR26 @RheumNow https://t.co/tFPNi0S8y8

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/cpusNcpYWd

Rituximab or Azathioprine for EGPA Maintenance? | RheumNow

Article

Mixed Drinks, Mixed Results (10.30.2026)

Jack Cush, MD Oct 30, 2026

Dr. Cush reviews the news and journal reports from this past week on RheumNow. This week on the podcast: hopeful guidelines for PMR; certainty about good & bad beverages in gout; mixed results in Sjogren's; non-lupus drugs saves lupus lives; and big hips sink ships in psoriatic arthritis

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/ZumTjOcrEa

Rituximab or Azathioprine for EGPA Maintenance? | RheumNow

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? The treatment of active TAK is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. https://t.co/J1EQHGzR5O https://t.co/w3rQ3AbrYt

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top? | RheumNow

Article

2026 BSR Guideline for the Treatment of Polymyalgia Rheumatica

Jack Cush, MD Oct 27, 2026

Toyoda and colleagues from the British Society for Rheumatology have published new PMR treatment guidelines to supercede the previously published 2009 BSR/BHPR PMR guidelines. These guidelines emphasize earlier specialist input, methotrexate as an option, and bone protection for all PMR patients

Article

Rituximab or Azathioprine for EGPA Maintenance?

Jack Cush, MD Oct 26, 2026

A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone.

Article

Takayasu Arteritis: Do TNFis or IL-6- inhibitors come out on top?

Brian Jaros, MD Oct 26, 2026

The treatment of active Takayasu arteritis (TAK) is imperative to quiet vascular inflammation and subsequently maintain vascular integrity while preventing vessel damage. Our upfront management of TAK, beyond glucocorticoids and conventional DMARDs, remains limited to two primary mechanistic

Biologic safety. Vasculitis mimics. What to do with seropositive arthralgia. RheumNow Live 2027 tackles the decisions you face in clinic. Jan. 30–31 | Onsite + virtual Registration NOW OPEN. Early Bird Pricing through 12/15/2026. https://t.co/zYYC2350tE https://t.co/mPI1o7sEcx

RheumNow

Are Concerns Over Avacopan Efficacy Overblown? Avacopan (Tavneos), the complement pathway inhibitor for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), appeared strongly effective in an Italian registry study, maybe a step toward putting questions about https://t.co/4w2INKPFeT

Giant Cell Arteritis market size was valued approximately $960 million USD in 2023 - read for interesting drug developments in GCA arena https://t.co/pEZ95je7r0 https://t.co/Dz8D5ieDQp

Giant Cell Arteritis Market Set for Significant Growth Through 2034 Driven by A…

Retrospective real world avacopan (AVCP) safety data from UK vasculitis center looked at AAV pts (RTX or CTX) rx w/ AVCP (n 133) or not AVCP (n 458). @1 yr AVCP had nonsignif incr in ALT >2xULN (15.8% v 11.4%) or >3xULN (11.3% v 6.3%; P 0.064) No diff in Alk phos, Bili, Hy's law https://t.co/ZZhpxdKhQl

Article

Remission – Believe it or Not (10.2.2026)

Jack Cush, MD Oct 02, 2026

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

GCA international survey of 155 specialists (rheums 51%; ophthal 33%). w/ GCA dx, ASA started in only 15%; w/ 69.5% uncertain. w/ visual loss, 93% Rheums, 85% Ophthal Rx w/ IVGC, followed by oral. Uncertainty for IV versus po GC seen in 68.5% https://t.co/sWZQv8yw3u https://t.co/08tdXxDve8

International practice patterns and beliefs concerning intravenous methylpredni…

Article

Steroid Delusions in Giant Cell Arteritis

Jack Cush, MD Sep 22, 2026

A real world analysis of drug use in giant cell arteritis (GCA) patients shows that despite intending to taper patients off glucocorticoids (GC) by 24 months, 75% remained on GCs for ≥ 48 months.

Article

Early RA Referral Clinics Work (9.18.2026)

Jack Cush, MD Sep 18, 2026

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

Dr John Stone grand rounds Kroc lecture #wustlRheum. Pearls: -IgG4RD can manifest as a variable vasculitis -Men have worse disease -Histology will not show necrosis or neutrophils -IgG4 levels will rise as the disease progress (>5X) -Rx with B cell therapy @alhkim @RheumNow https://t.co/GUw348OrrA

https://x.com/KDAO2011/status/2098055334883389446/photo/1

Article

A Day of Infamy (9.11.2026)

Jack Cush, MD Sep 11, 2026

Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz

DERM on RheumNow PODCAST (August 2026) The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, CTD skin disorders. Dermatology drugs, biologics, and JAK inhibitors - their use, https://t.co/u2sJqCgDJS

Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/paUlV4kdwJ

Article

NME: New Molecular Entities (8.28.2026)

Jack Cush, MD Aug 28, 2026

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. Take this week's RheumIQ and test your knowledge!

Article

Secukinumab in Polymyalgia Rheumatica

Jack Cush, MD Aug 27, 2026

Polymyalgia rheumatica (PMR) is a common disorder of the elderly that responds well to glucocorticoids (GC), but is plagued by an inability to wean off of GCs.

Aortic inflammation (Aortopathies) occurs in autoimmune rheumatic diseases (ARD) including Takayasus, #GCA, SLE, RA, AS, SSc, relapsing polychondritis, Cogan’s syndr, Behçet’s, & IgG4-related disease). Dx imaging options: CTA, MRI, & PET/CT. Underlying path may be granulomatous, https://t.co/lKBhEnTcKB

Registry Data Shows Liver Risk With Avacopan A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from https://t.co/nHF6RVpq2Z